Table 4 Comparison of treatments and SDI scores between SLE patients with and without thrombotic events.

From: Risk factors for thrombotic events in Korean patients with systemic lupus erythematosus

 

All (n = 259)

Thrombotic events (n = 27)

No event (n = 232)

P-value

Medication (%)

Mean daily prednisolone > 5 mg/day

93 (36.2)

20 (76.9)

73 (31.6)

 < 0.001

Hydroxychloroquine > 80% during follow-up

224 (86.5)

22 (81.5)

202 (87.1)

0.422

Immunosuppressive agents

145 (56.0)

19 (70.4)

126 (54.3)

0.112

Cyclophosphamide

55 (21.2)

7 (25.9)

48 (20.7)

0.340

ACEi or ARB

93 (34.1)

14 (51.9)

79 (34.1)

0.068

Statin

41 (15.8)

6 (22.2)

35 (15.1)

0.336

Anticoagulation or antiplatelet drugs

55 (21.2)

10 (37.0)

45 (19.4)

0.034

SDIa

0.99 ± 1.10

2.07 ± 1.43

0.86 ± 0.98

 < 0.001

  1. aSDI was measured before development of thrombotic events or at the last visit.
  2. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; SLE, systemic lupus erythematosus.
Back to article page